• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[通过纤溶试验鉴别正常人群与有特发性血栓栓塞病史患者队列]

[Differentiation of a normal population and of a cohort of patients presenting with a history of idiopathic thromboembolism as identified with fibrinolytic tests].

作者信息

Nicoloso G, Hauert J, Kruithof E K, van Melle G, Bachmann F

机构信息

Département de médecine, CHUV, Lausanne.

出版信息

Schweiz Med Wochenschr. 1988 Jan 31;118(4):122-4.

PMID:3125604
Abstract

To identify persons at risk for development of thromboembolic disease, fibrinolytic and blood coagulation parameters of normal controls (n = 40) and patients (n = 40) have been compared. Four fibrinolytic parameters, i.e. fibrinolytic activity at rest (FAr), fibrinolytic response after 10 minutes of venous occlusion (delta FA10'), and resting antigenic levels of the plasmatic inhibitor of the plasminogen activators (PAI-1) and of urokinase (u-PA), showed significant differences between the two study groups. The separate and combined discriminant analysis of FAr and delta FA10' values revealed that individuals with FAr below 0.63 UI/ml or a delta FA10' below 0.98 UI/ml are at risk for development of thromboembolic disease.

摘要

为了识别有发生血栓栓塞性疾病风险的人群,对40名正常对照者和40名患者的纤溶和凝血参数进行了比较。四个纤溶参数,即静息纤溶活性(FAr)、静脉闭塞10分钟后的纤溶反应(δFA10')以及纤溶酶原激活物的血浆抑制剂(PAI-1)和尿激酶(u-PA)的静息抗原水平,在两个研究组之间显示出显著差异。对FAr和δFA10'值进行单独和联合判别分析发现,FAr低于0.63 UI/ml或δFA10'低于0.98 UI/ml的个体有发生血栓栓塞性疾病的风险。

相似文献

1
[Differentiation of a normal population and of a cohort of patients presenting with a history of idiopathic thromboembolism as identified with fibrinolytic tests].[通过纤溶试验鉴别正常人群与有特发性血栓栓塞病史患者队列]
Schweiz Med Wochenschr. 1988 Jan 31;118(4):122-4.
2
Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.青少年血液纤溶成分的年龄依赖性以及低剂量口服避孕药对青少年凝血和纤溶的影响。
Thromb Haemost. 1988 Dec 22;60(3):361-4.
3
Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.正常受试者的纤维蛋白溶解——纤溶酶原激活物抑制剂与纤维蛋白溶解系统其他成分的比较
Thromb Haemost. 1988 Apr 8;59(2):299-303.
4
[Thromboembolic disease and anomalies of fibrinolysis].[血栓栓塞性疾病与纤维蛋白溶解异常]
Ann Med Interne (Paris). 1986;137(6):471-4.
5
Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.不明原因早期复发性流产女性的血浆纤溶激活剂及其抑制剂
J Lab Clin Med. 1993 Nov;122(5):606-15.
6
[Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].[冠状动脉溶栓治疗引起的止血和纤溶状态的系列变化]
J Cardiol. 1993;23(4):335-41.
7
Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.某些骨髓增殖性综合征中的纤溶酶原激活剂(组织型纤溶酶原激活剂和尿激酶型纤溶酶原激活剂)及纤溶酶原激活剂抑制剂(PAI - 1和PAI - 2)
Med Sci Monit. 2000 Jul-Aug;6(4):684-91.
8
Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.亚临床甲状腺疾病中的血液凝固、纤溶活性和血脂谱:亚临床甲状腺功能亢进会增加血浆凝血因子X活性。
Clin Endocrinol (Oxf). 2006 Mar;64(3):323-9. doi: 10.1111/j.1365-2265.2006.02464.x.
9
Fibrinolytic activity and protein C in preeclampsia.先兆子痫中的纤溶活性和蛋白C
Thromb Haemost. 1986 Jun 30;55(3):314-7.
10
Diurnal variation of the fibrinolytic system.纤维蛋白溶解系统的昼夜变化。
Thromb Haemost. 1988 Jun 16;59(3):495-9.